Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha; Alexander T H Wu; Wei Hwa Lee; Liang Shun Wang; Wan Wan Lin; Chiou Chung Yuan; Chi-Tai Yeh

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Muhammad Ary Zucha, Alexander T H Wu, Wei Hwa Lee, Liang Shun Wang, Wan Wan Lin, Chiou Chung Yuan, Chi-Tai Yeh

Research output: Contribution to journal › Article › peer-review

Abstract

According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

Original language	English
Pages (from-to)	13255-13268
Number of pages	14
Journal	Oncotarget
Volume	6
Issue number	15
Publication status	Published - 2015

Keywords

Bruton's tyrosine kinase (Btk)
Cancer stem cell (CSC)
Cisplatin
Ibrutinib
Ovarian cancer
Spheroids

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{bcb1182d0a184149b2195fcb2ac21554,

title = "Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer",

abstract = "According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.",

keywords = "Bruton's tyrosine kinase (Btk), Cancer stem cell (CSC), Cisplatin, Ibrutinib, Ovarian cancer, Spheroids",

author = "Zucha, {Muhammad Ary} and Wu, {Alexander T H} and Lee, {Wei Hwa} and Wang, {Liang Shun} and Lin, {Wan Wan} and Yuan, {Chiou Chung} and Chi-Tai Yeh",

year = "2015",

language = "English",

volume = "6",

pages = "13255--13268",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "15",

}

TY - JOUR

T1 - Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

AU - Zucha, Muhammad Ary

AU - Wu, Alexander T H

AU - Lee, Wei Hwa

AU - Wang, Liang Shun

AU - Lin, Wan Wan

AU - Yuan, Chiou Chung

AU - Yeh, Chi-Tai

PY - 2015

Y1 - 2015

N2 - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

AB - According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.

KW - Bruton's tyrosine kinase (Btk)

KW - Cancer stem cell (CSC)

KW - Cisplatin

KW - Ibrutinib

KW - Ovarian cancer

KW - Spheroids

UR - http://www.scopus.com/inward/record.url?scp=84931092005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931092005&partnerID=8YFLogxK

M3 - Article

C2 - 26036311

AN - SCOPUS:84931092005

SN - 1949-2553

VL - 6

SP - 13255

EP - 13268

JO - Oncotarget

JF - Oncotarget

IS - 15

ER -

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this